Potency and timing of antiviral therapy as determinants of duration of SARS CoV-2 shedding and intensity of inflammatory response

Ashish Goyal; E. Fabian Cardozo-Ojeda; Joshua T Schiffer

Broadly neutralizing antibody predictions. We next simulated a single infusion of broadly neutralizing antibodies with prolonged half-life. Broadly neutralizing antibodies are designed to stop infection of new cells rather than eliminate viral replication. We used a dual compartment PK model for (Fig. S5a) , estimated antibody levels over time following a single dose (Fig. S5b) , generated theoretical dose response curves (Fig. S5c) , and then projected antibody efficacy over time (Fig. S5d) . The predicted efficacy of therapy on shedding again was dependent on timing of treatment and the in vivo EC50 (Fig. S6a-d) . Once again, to lower duration of shedding and the number of effector cells depended on therapeutic potency, while effective lowering of viral area under the curve required extremely early initiation of potent treatment ( Fig. S6e-g) .